NSEGeneral Updates11 Sept 2026 · 11 Sept 2026, 01:45 pm

General Updates

Senores Pharmaceuticals Limited · SENORES

✦ AI SummaryRegulatory

Senores Pharmaceuticals Limited has informed the Exchange about the successful completion of a USFDA inspection at its subsidiary company's manufacturing facility in Vadodara. The inspection was conducted from September 7 to September 11, 2026, and resulted in one minor procedural observation with no GMP-related issues.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Senores Pharmaceuticals Limited has informed the Exchange about Successful Completion of USFDA Inspection

Attachments (1)

📄

SENORES_11092026134434_Intimation.pdf

pdf

Download →
View document text
Date: September 11, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Dear Sir/Madam, Subject.: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015‐ Successful Completion of USFDA Inspection Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to announce that the United States Food and Drug Administration (USFDA) has successfully completed its inspection at the manufacturing facility of Apnar Pharma Private Limited, Subsidiary Company, situated at Vadodara, from Monday, September 07, 2026, till Friday, September 11, 2026 with one minor procedural and no GMP-related observation. The Subsidiary Company will submit its response within the stipulated timeframe. We request you to take the above information on record. Thanking you. For Senores Pharmaceuticals Limited Shilpa Sharma Company Secretary and Compliance Officer ICSI Membership No.: A34516 Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad‐380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263